In our research, we discovered that DTYMK was able to reliably activate all six different kinds of immune cells (neutrophils, CD8+ T cells, macrophages, dendritic cells, CD4+ T cells, and B cells) in most kinds of cancer, except in BLCA and CHOL. This evidence concerns the gene CD8A and bladder transitional cell carcinoma.